NASDAQ:INSY - INSYS Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New INSYS Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INSY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INSY

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for INSYS Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for INSY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in INSYS Therapeutics. This rating has held steady since May 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2019Janney Montgomery ScottDowngradeBuy ➝ NeutralHigh
3/8/2019Piper Jaffray CompaniesSet Price TargetSell$4.00Medium
3/8/2019Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$9.00 ➝ $7.00High
1/22/2019Cantor FitzgeraldInitiated CoverageOverweight$4.40High
1/19/2019Janney Montgomery ScottSet Price TargetBuy$11.00High
12/19/2018Janney Montgomery ScottReiterated RatingBuy ➝ Buy$11.00High
8/11/2018Piper Jaffray CompaniesSet Price TargetSell$4.00Low
8/10/2018Jefferies Financial GroupReiterated RatingBuy$10.00Low
8/9/2018Royal Bank of CanadaReiterated RatingBuy$9.00Medium
5/9/2018OppenheimerReiterated RatingHoldLow
3/11/2018OppenheimerReiterated RatingHoldMedium
3/9/2018Piper Jaffray CompaniesDowngradeNeutral ➝ UnderweightHigh
11/12/2017OppenheimerReiterated RatingHoldN/A
11/3/2017Jefferies Financial GroupLower Price TargetBuy$14.00 ➝ $11.00N/A
10/30/2017OppenheimerReiterated RatingHoldN/A
10/27/2017Royal Bank of CanadaSet Price TargetBuy$8.00N/A
10/11/2017Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$14.00N/A
8/4/2017Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.00Medium
8/3/2017OppenheimerReiterated RatingHoldMedium
7/26/2017Piper Jaffray CompaniesSet Price TargetHold$10.00Medium
7/4/2017OppenheimerReiterated RatingHoldHigh
6/9/2017Jefferies Financial GroupReiterated RatingBuy$14.00Low
6/3/2017Royal Bank of CanadaSet Price TargetBuy$16.00High
5/10/2017Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$20.00 ➝ $10.00Low
4/28/2017Royal Bank of CanadaReiterated RatingBuy$16.00Medium
4/6/2017OppenheimerReiterated RatingHoldLow
4/4/2017Jefferies Financial GroupLower Price TargetBuy$16.00 ➝ $14.00Low
3/27/2017Royal Bank of CanadaSet Price TargetBuy$16.00Low
3/16/2017Jefferies Financial GroupReiterated RatingBuy$16.00High
1/19/2017OppenheimerReiterated RatingN/A
1/8/2017Royal Bank of CanadaSet Price TargetBuy$16.00N/A
12/21/2016Royal Bank of CanadaReiterated RatingOutperform$23.00 ➝ $16.00N/A
12/21/2016Royal Bank of CanadaLower Price TargetOutperform$23.00 ➝ $16.00N/A
12/9/2016Royal Bank of CanadaReiterated RatingBuy$23.00N/A
(Data available from 11/27/2016 forward)

News Sentiment Rating

-0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/28/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
INSYS Therapeutics logo
Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $23,687,640.18
Low: $0.23
High: $65,799,000.00

52 Week Range

Now: N/A

Volume

N/A

Average Volume

9,520,592 shs

Market Capitalization

$21.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.21

Frequently Asked Questions

What sell-side analysts currently cover shares of INSYS Therapeutics?

The following equities research analysts have issued stock ratings on INSYS Therapeutics in the last twelve months:
View the latest analyst ratings for INSY.

What is the current price target for INSYS Therapeutics?

0 Wall Street analysts have set twelve-month price targets for INSYS Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for INSYS Therapeutics in the next year.
View the latest price targets for INSY.

What is the current consensus analyst rating for INSYS Therapeutics?

INSYS Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for INSY.

What other companies compete with INSYS Therapeutics?

How do I contact INSYS Therapeutics' investor relations team?

INSYS Therapeutics' physical mailing address is 1333 S. Spectrum Blvd Suite 100, Chandler AZ, 85286. The specialty pharmaceutical company's listed phone number is 480-500-3127 and its investor relations email address is [email protected] The official website for INSYS Therapeutics is www.insysrx.com.